Moderna Stock News

Moderna Inc. beat earnings and revenue expectations for the fourth quarter of 2021 after announcing Thursday that its COVID-19 vaccine brought in nearly $7 billion in product sales during the final three months of the year. Moderna had a profit of $4.8 billion, or $11.29 per share, in the fourth quarter of 2021, after reporting a loss of $272 million, or 69 cents per share, in the fourth quarter of 2020. The FactSet consensus was $9.96. Moderna reported $7.2 billion in total revenue for the final quarter of 2021, up from $571 million in the same quarter of 2020, which is when the company''s COVID-19 vaccine first received authorization in the U.S. The FactSet consensus was $6.8 billion. Moderna said 297 million doses of its vaccine generated $6.9 billion in product sales for the quarter. (The rest of the revenue came from grant and collaboration revenue.) Moderna''s stock is down 6.2% over the past year, while the broader S&P 500 is up 8.8.%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

Moderna said it now sees sales of Spikevax rising to $19 billion this year, with additional signed options of approximately $3 billion.

Moderna on Thursday said it expects to sell at least $19 billion of its Covid-19 vaccine this year, after reporting fourth-quarter earnings that blew out analysts'' earnings and revenue estimates.

Moderna press release (MRNA): Q4 GAAP EPS of $11.29 beats by $1.68.Revenue of $7.21B (+1162.7% Y/Y) beats by $480M.Moderna (MRNA) increased its 2022 signed advance purchase…

2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.

Also: A rundown of everything you need to know about Russia''s attack on Ukraine. Read More

Pre-open movers U.S. stock futures traded sharply lower in early pre-market trade after Russia’s President Vladimir Putin announced that the country’s armed forces would carry out a “special military operation” in Ukraine. Investors are awaiting earnings results from Moderna, Inc. (NASDAQ: MRNA ), Alibaba Group Holding Limited (NYSE: BABA ) and Dell Technologies Inc. (NYSE: DELL ). Data on initial jobless claims, Gross Domestic Product and Chicago Fed National Activity Index will be released at 8:30 a.m. ET. Data on new home sales for January will be released at 10:00 a.m. ET. The Kansas City Fed manufacturing index for February is scheduled for release at 11:00 a.m. ET. Federal Reserve Bank of Richmond President Thomas Barkin is set to speak at 9:00 a.m. ET, while Federal Reserve Bank of Atlanta President Raphael Bostic will speak at 11:10 a.m. ET. Federal Reserve Bank of Cleveland President Loretta Mester and Federal Reserve Bank of Richmond President Thomas Barkin will speak at 12:00 p.m.

Some of the stocks that may grab investor focus today are: Wall Street expects Moderna, Inc. (NASDAQ: MRNA ) to report quarterly earnings at $9.90 per share on revenue of $6.79 billion before the opening bell. Moderna shares fell 2.7% to $132.10 in after-hours trading. eBay Inc. (NASDAQ: EBAY ) reported upbeat earnings for its fourth quarter, but issued weak outlook for the current quarter. eBay shares dipped 7.8% to $50.35 in the after-hours trading … Full story available on Benzinga.com

The Moderna COVID-19 vaccine has now been approved as the primary course for children aged 6 to 11 in Australia. Speaking at the press conference on Feb. 23, Health Minister Greg Hunt said Moderna gives “more choice and flexibility” for parents along with the Pfizer vaccine which is approved for children aged 5 and older. […]

German Health Insurer Reveals ''Alarming'' Underreporting Of Vaccine Side-Effects A large German health insurance provider revealed on Wednesday that Covid-19 vaccine side-effects are vastly underreported, according to Welt . After analyzing data from over 10 million individuals, BKK ProVita board member Andreas Schöfbeck, over a 7.5 month period beginning in early 2021, 216,695 policyholders out of 10.9 million were treated for vaccine side-effects. This compares to 244,576 reports out of 61.4 million reported by the Paul Ehrlich Institute - a German federal agency. Germany has a population of around 83 million people. Schöfbeck called the data an "alarm signal," adding "The numbers determined are significant and urgently need to be checked for plausibility." " The data available to our company gives us reason to believe that there is a very considerable under-recording of suspected cases of vaccination side-effects after they received the [COVID-19] vaccine. " “If these figures are applied to the year as a whole and to” the entire population of Germany, Schöfbeck estimated, then “ probably 2.5-3 million people in Germany been under medical treatment because of vaccination side effects after [COVID-19] vaccination. ” As Jack Phillips of The Epoch Times notes: Schöfbeck concluded that based on their data, “there is a significant underreporting of vaccination side-effects ” in Germany.

Moderna and Thermo Fisher Enter Long-Term Collaboration

The Centers for Disease Control and Prevention (CDC) has officially altered its recommended COVID-19 vaccination schedule in a bid to address concerns about the elevated rate of heart inflammation seen among many groups who have gotten a vaccine. The two most widely administered COVID-19 vaccines in the country are made by Moderna and Pfizer. Recipients […]

A new COVID-19 vaccine option could be on its way to the market.

The company''s earnings report is due out before the open tomorrow

This article was originally published on TipRanks.com. The post Moderna Signs Agreement to Sell COVID-19 Vaccine in Latin America appeared first on Smarter Analyst .